Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth – A Randomized Clinical Trial

JAMA Pediatrics
November 2018, Vol 172, No. 11, Pages 997-1108
http://archpedi.jamanetwork.com/issue.aspx

Original Investigation
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth – A Randomized Clinical Trial
Nicholas Wood, MB, BS, PhD; Terry Nolan, MB, BS, PhD; Helen Marshall, MB, BS, MD; et al.
JAMA Pediatr. 2018;172(11):1045-1052. doi:10.1001/jamapediatrics.2018.2349
This randomized clinical trial compares IgG antibody responses to vaccine antigens at age 6, 10, 24, and 32 weeks between newborn infants receiving the monovalent acellular pertussis vaccine and the hepatitis B vaccine and those receiving the hepatitis B vaccine alone.